BIOLINQ Trademark

Trademark Overview

On Monday, January 23, 2023, a trademark application was filed for BIOLINQ with the United States Patent and Trademark Office. The USPTO has given the BIOLINQ trademark a serial number of 97764182. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Saturday, November 1, 2025. This trademark is owned by Biolinq Incorporated. The BIOLINQ trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing temporary use of online non-downloadable software used with wearable sensors for monitoring blood glucose and managing diabetes¸ not relating to incontinence or geriatric care
biolinq

General Information

Serial Number97764182
Word MarkBIOLINQ
Filing DateMonday, January 23, 2023
Status680 - APPROVED FOR PUBLICATION
Status DateSaturday, November 1, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesProviding temporary use of online non-downloadable software used with wearable sensors for monitoring blood glucose and managing diabetes¸ not relating to incontinence or geriatric care

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, February 12, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBiolinq Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92121

Trademark Events

Event DateEvent Description
Thursday, January 26, 2023NEW APPLICATION ENTERED
Sunday, February 12, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 22, 2023ASSIGNED TO EXAMINER
Saturday, September 23, 2023NON-FINAL ACTION WRITTEN
Saturday, September 23, 2023NON-FINAL ACTION E-MAILED
Saturday, September 23, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, December 26, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 26, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 27, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 14, 2024FINAL REFUSAL WRITTEN
Wednesday, August 14, 2024FINAL REFUSAL E-MAILED
Wednesday, August 14, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, November 6, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Wednesday, November 6, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, February 11, 2025EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, February 11, 2025EX PARTE APPEAL-INSTITUTED
Tuesday, October 28, 2025EXPARTE APPEAL DISMISSED AS MOOT
Tuesday, October 28, 2025EXPARTE APPEAL TERMINATED
Saturday, November 1, 2025APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords

biolinq diabetes managing glucose relating incontinence care geriatric blood monitoring downloadable